Cargando…
Management of toxicity to isoform α-specific PI3K inhibitors
Alterations in the phosphoinositide 3-kinase (PI3K)/AKT pathway are frequently found in cancer and are especially common in breast cancer, where it is estimated that 70% of tumors have some type of genetic alteration that could lead to pathway hyperactivation. A variety of PI3K pathway inhibitors ha...
Autores principales: | Nunnery, S E, Mayer, I A |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6923786/ https://www.ncbi.nlm.nih.gov/pubmed/31626273 http://dx.doi.org/10.1093/annonc/mdz440 |
Ejemplares similares
-
Structural Determinants of Isoform Selectivity in PI3K Inhibitors
por: Miller, Michelle S., et al.
Publicado: (2019) -
The role of PI3Kα isoform in cardioprotection
por: Rossello, Xavier, et al.
Publicado: (2017) -
Identification of ARUK2002821 as an isoform-selective PI5P4Kα inhibitor
por: Willems, Henriëtte M. G., et al.
Publicado: (2023) -
PI3Kα Inhibitors That Inhibit Metastasis
por: Schmidt-Kittler, Oleg, et al.
Publicado: (2010) -
Management Strategies for Hyperglycemia Associated with the α-Selective PI3K Inhibitor Alpelisib for the Treatment of Breast Cancer
por: Tankova, Tsvetalina, et al.
Publicado: (2022)